Energenesis Biomedical Co. Ltd.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel … Read more
Energenesis Biomedical Co. Ltd. (6657) - Total Assets
Latest total assets as of September 2025: NT$1.03 Billion TWD
Based on the latest financial reports, Energenesis Biomedical Co. Ltd. (6657) holds total assets worth NT$1.03 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Energenesis Biomedical Co. Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Energenesis Biomedical Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Energenesis Biomedical Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Energenesis Biomedical Co. Ltd.'s total assets of NT$1.03 Billion consist of 88.1% current assets and 11.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 51.8% |
| Accounts Receivable | NT$2.00 Million | 0.3% |
| Inventory | NT$750.00K | 0.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$13.67 Million | 1.8% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Energenesis Biomedical Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Energenesis Biomedical Co. Ltd.'s current assets represent 88.1% of total assets in 2024, an increase from 80.4% in 2019.
- Cash Position: Cash and equivalents constituted 51.8% of total assets in 2024, up from 13.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 1.8% of total assets.
Energenesis Biomedical Co. Ltd. Competitors by Total Assets
Key competitors of Energenesis Biomedical Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Energenesis Biomedical Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Energenesis Biomedical Co. Ltd. generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Energenesis Biomedical Co. Ltd. is currently not profitable relative to its asset base.
Energenesis Biomedical Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 34.47 | 21.08 | 20.67 |
| Quick Ratio | 34.44 | 21.06 | 20.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$914.78 Million | NT$ 550.83 Million | NT$ 479.12 Million |
Energenesis Biomedical Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Energenesis Biomedical Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.20 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -5.8% |
| Total Assets | NT$780.64 Million |
| Market Capitalization | $98.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Energenesis Biomedical Co. Ltd.'s assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Energenesis Biomedical Co. Ltd.'s assets decreased by 5.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Energenesis Biomedical Co. Ltd. (2019–2024)
The table below shows the annual total assets of Energenesis Biomedical Co. Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$780.64 Million | -5.78% |
| 2023-12-31 | NT$828.57 Million | +31.34% |
| 2022-12-31 | NT$630.86 Million | -28.78% |
| 2021-12-31 | NT$885.81 Million | +25.57% |
| 2020-12-31 | NT$705.45 Million | -13.29% |
| 2019-12-31 | NT$813.61 Million | -- |